Personalized approach to infertility treatment in a patient with polyendocrine metabolic ovarian syndrome and chronic pancreatitis

Czech version

Authors: S. Šimová ; Lenka Mekiňová ; Michal Ješeta ; E. Lousová ; Robert Hudeček
Authors‘ workplace: Klinika gynekologie, porodnictví a neonatologie LF MU a FN Brno
Published in: Ceska Gynekol 2026; 91(4): 322-325
Category: Case Report
doi: https://doi.org/10.48095/cccg2026322

Overview

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in fertile women, with an estimated prevalence of 10–15%. It is a heterogeneous disease characterized by a complex pathogenesis. Genetic predisposition, neuroendocrine regulation disorders, and environmental influences play a key role. Dysregulation of the hypothalamic–pituitary–ovarian axis occurs with subsequent chronic anovulation, hyperandrogenemia, and metabolic abnormalities. Phenotypic variability reflects different pathophysiological mechanisms –⁠ based on genomic association studies, three subtypes of PCOS can be distinguished: reproductive, metabolic, and indeterminate. PCOS is one of the main causes of female infertility and a risk factor for the development of cardiometabolic diseases. Objective: The aim of the article is to summarize current recommendations of the European Society of Human Reproduction and Embryology (ESHRE 2023) regarding the diagnosis and treatment of polyendocrine metabolic ovarian syndrome (PMOS) in patients with fertility disorders and to demonstrate their practical application through a selected clinical case.

Keywords:

anti-Müllerian hormone – hyperandrogenism – polyendocrine metabolic ovarian syndrome – sterility – treatment of anovulation

Sources

1. Teede HJ, Khomami MB, Morman R et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet 2026; 407 (10545): 2329–2339. doi: 10.1016/S0140-6736 (26) 00717-8.

2. Teede HJ, Tay CT, Laven J et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2023; 38 (9): 1655–1679. doi: 10.1093/humrep/dead156.

3. Parker J. Pathophysiological effects of contemporary lifestyle on evolutionary-conserved survival mechanisms in polycystic ovary syndrome. Life 2023; 13 (4): 1056. doi: 10.3390/life13041056.

4. Mekiňová L, Ješeta M, Crha I et al. Selected pathological conditions affecting endometrial receptivity. Ceska Gynekol 2022; 87 (6): 416–422. doi: 10.48095/cccg2022416.

5. Day F, Karaderi T, Jones MR et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet 2018; 14 (12): 1007813. doi: 10.1371/journal.pgen.1007813.

6. Dapas M, Lin FT, Nadkarni GN et al. Distinct subtypes of polycystic ovary syndrome with novel genetic associations: an unsupervised, phenotypic clustering analysis. PLoS Med 2020; 17 (6): 1003132. doi: 10.1371/journal.pmed.1003132.

7. Burns K, Mullin BH, Moolhuijsen LM et al. Body mass index stratified meta-analysis of genome-wide association studies of polycystic ovary syndrome in women of European ancestry. BMC Genomics 2024; 25 (1): 208. doi: 10.1186/s12864-024-09990-w.

8. Yesiladali M, Yazici MG, Attar E e tal. Differentiating polycystic ovary syndrome from adrenal disorders. Diagnostics (Basel) 2022; 12 (9): 2045. doi: 10.3390/diagnostics12092045.

9. Chahal N, Geethadevi A, Kaur S et al. Direct impact of gonadotropins on glucose uptake and storage in preovulatory granulosa cells: implications in the pathogenesis of polycystic ovary syndrome. Metabolism 2021; 115 : 154458. doi: 10.1016/j.metabol.2020.154458.

10. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012; 27 (5): 1327–1231. doi: 10.1093/humrep/des042.

11. Bai X, Zheng L, Li D et al. Research progress of endometrial receptivity in patients with polycystic ovary syndrome: a systematic review. Reprod Biol Endocrinol 2021; 19 (1): 122. doi: 10.1186/s12958-021-00802-4.

12. Herman R, Kravos NA, Jensterle M et al. Metformin and insulin resistance: a review of the underlying mechanisms behind changes in GLUT4--mediated glucose transport. Int J Mol Sci 2022; 23 (3): 1264. doi: 10.3390/ijms23031264.

13. Pourali L, Ayati S, Tavakolizadeh S et al. Clomiphene citrate versus letrozole with gonadotropins in intrauterine insemination cycles: a randomized trial. Int J Reprod Biomed 2017; 15 (1): 49–54.

14. Dorn C, van der Ven H. Clomiphene citrate versus gonadotrophins for ovulation stimulation. Reprod Biomed Online 2005; 10 (Suppl 3): 37–43. doi: 10.1016/s1472-6483 (11) 60389-1.

15. Teede HJ, Misso ML, Costello MF et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018; 110 (3): 364–379. doi: 10.1016/j.fertnstert.2018.05.004.

16. Zhai J, Liu CX, Tian ZR et al. Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. Biol Reprod 2012; 87 (2): 29. doi: 10.1095/biolreprod.112.099788.

17. Baradwan S, Abuzaid M, Sabban H et al. Transvaginal needle versus laparoscopic ovarian drilling in hormonal profile and pregnancy outcomes of polycystic ovary syndrome: a systematic review and meta-analysis. J Gynecol Obstet Hum Reprod 2023; 52 (6): 102606. doi: 10.1016/j.jogoh.2023.102606.

18. Della Corte L, Boccia D, Palumbo M et al. Is there still a place for surgery in patients with PCOS? A review. Life (Basel) 2023; 13 (6): 1270. doi: 10.3390/life13061270.

19. Bordewijk EM, Ng KY, Rakic L et al. Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2020; 2 (2): CD001122. doi: 10.1002/14651858.CD001122.pub5.